| Combination of | |
|---|---|
| Linopristin | Antibiotic |
| Flopristin | Antibiotic |
| Clinical data | |
| Other names | NXL103; XRP 2868 |
| Identifiers | |
| CAS Number | |
Linopristin/flopristin (development codesNXL103 andXRP 2868) is an experimental drug candidate underdevelopment by Novexel. It is an oralstreptograminantibiotic that has potentin vitro activity against certainGram-positive bacteria includingmethicillin resistantStaphylococcus aureus (MRSA),[1] as well as the important respiratory pathogens includingpenicillin-,macrolide- andquinolone-resistant strains.[2][3] It is a combination oflinopristin andflopristin.[4]
Positive results have been reported from aphase II trial comparing it withamoxicillin.[2] Another phase II trial began in 2010 comparing it withlinezolid for treatment ofacute bacterial skin and skin structure infections (ABSSSI).[5] No development activity has been reported since 2015.[6]
 | This systemicantibiotic-related article is astub. You can help Wikipedia byexpanding it. |